Previous 10 | Next 10 |
2023-03-06 15:07:51 ET Another week of trading is underway and marks the first full week of March 2023. Whether you’re trading penny stocks or searching for the next mega-cap tech stocks to buy, research is the first place to begin the trading journey. Obviously, when it comes to che...
Immunic to Participate in Investor and Scientific Conferences in March PR Newswire NEW YORK , March 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies f...
Immunic, Inc. (IMUX) Q4 2022 Earnings Conference Call February 23, 2023, 08:00 ET Company Participants Jessica Breu - Head, IR & Communications Daniel Vitt - CEO, President & Director Glenn Whaley - CFO Conference Call Participants Yasmeen Rahimi - ...
Immunic press release ( NASDAQ: IMUX ): FY GAAP EPS of -$3.78 misses by $0.88 . Cash, Cash Equivalents and Investments as of December 31, 2022, were $116.4 million. With these funds, Immunic expects to be able to fund its operations into the fourth quarter of 2024. For f...
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update PR Newswire – Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER...
Immunic ( NASDAQ: IMUX ) is scheduled to announce FY earnings results on Thursday, February 23nd, before markets open. The consensus EPS Estimate is -$2.90 (+26.2% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revisio...
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 PR Newswire – Long-Term Open-Label Treatment With Vidofludimus Calcium Was Associated With a Low Rate of Confirmed Disability Wo...
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on February 23, 2023 – NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Immunic, ...
Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need PR Newswire – Co...
Summary Interim results from the phase 2 CALLIPER study using IMU-838 for treatment of patients with Progressive MS are expected in the 2nd half of 2023; topline results are end of 2024. Final results from the phase 3 ENSURE study, using IMU-838 for the treatment of patients with relaps...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...